2024-10-19 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Overview**

Johnson & Johnson (JNJ) is a multinational healthcare company that develops, manufactures, and sells pharmaceutical products, medical devices, and consumer healthcare products. 

The stock's **cumulative return** is 37.26%, trailing the S&P 500 (VOO) by a significant 99.71%. This places its **relative divergence** at 5.06%, indicating that JNJ's performance is currently at the lower end of its historical range compared to the S&P 500.

**2. Recent Price Action**

* **Closing Price:** 164.47
* **5-day Moving Average:** 163.18
* **20-day Moving Average:** 161.84
* **60-day Moving Average:** 162.37

The stock's recent price action suggests **mild upward momentum** as the closing price sits above all three moving averages. 

**3. Technical Indicators**

* **RSI:** 59.63 - This indicates a **neutral sentiment** for JNJ, neither overbought nor oversold.
* **PPO:** 0.24 -  The positive PPO suggests a **potential upward trend**, but a closer look at the relative divergence reveals a -3.68 change over the past 20 days, hinting at a **short-term downward pullback**. 
* **Expected Return:** 0.0% -  This indicates **no significant expected return** over the next five years compared to the S&P 500.

**4. Recent Earnings and Outlook**

| Date     | EPS      | Revenue           |
|----------|----------|--------------------|
| 2024-07-25 | 1.95     | $22.45 Billion     |
| 2024-05-01 | 1.35     | $21.38 Billion     |
| 2024-02-16 | 1.68     | $21.39 Billion     |
| 2023-10-27 | 10.32    | $21.35 Billion     |
| 2024-02-16 | 10.32    | $21.35 Billion     |

While the latest earnings report of $1.95 EPS and $22.45 Billion in revenue showcases a **positive growth trend**, it **missed analysts' expectations** for both metrics. 

The company's recent earnings have been influenced by the **spinoff of its consumer health business** in November 2023, making it difficult to directly compare current performance with historical data. 

**5. News and Recent Issues**

* **Recent Market Outlook:** The stock is currently facing **mixed sentiment** from analysts. Some analysts maintain a **buy rating**, citing JNJ's **strong dividend history**, **stable business model**, and **continued growth potential** in pharmaceuticals and medical devices. 
* **Analyst Opinions:**  **FINBOLD** reports an **average price target of $182.63**, suggesting **potential upside** for the stock. 
* **Performance Highlights:** Despite a recent pullback, JNJ remains a **popular dividend-paying stock**, and investors appreciate its **resilience** during turbulent market conditions.  

**6. Comprehensive Analysis**

JNJ is a stable company with a strong brand and a diversified portfolio. However, its recent underperformance relative to the market, coupled with the recent spinoff, has introduced some uncertainty. 

The stock is trading at a neutral technical indicator level, suggesting **limited potential for significant upside** in the short term. The missed earnings expectations could further fuel this downward trend, although the long-term growth prospects remain positive.

**7. Conclusion**

While JNJ might not be a top performer in the short term, it remains a **reliable dividend-paying stock** with a **strong track record** and a **resilient business model**. Investors seeking **long-term stability and dividends** might find JNJ a suitable addition to their portfolio. However, those seeking significant short-term gains might want to explore other opportunities.
